The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection

C da Cunha-Bang, N Kirkby, Majken Sønderholm, S S Sørensen, H Sengeløv, M Iversen, A Rasmussen, F Gustafsson, Camilla Frederiksen, J Kjaer, A Cozzi Lepri, J D Lundgren

18 Citationer (Scopus)

Abstract

(Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004-2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC(50) ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio
OriginalsprogEngelsk
TidsskriftAmerican Journal of Transplantation
Vol/bind13
Udgave nummer2
Sider (fra-til)458-66
Antal sider9
ISSN1600-6135
DOI
StatusUdgivet - 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'The time course of development and impact from viral resistance against ganciclovir in cytomegalovirus infection'. Sammen danner de et unikt fingeraftryk.

Citationsformater